Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODULO trial: doravirine/lamivudine vs dolutegravir/lamivudine maintenance ART
2024-515793-27-01Phase 3Authorised
- Sponsor
- Centre de Recherches et d'Etudes sur la Pathologie Tropicale et le Sida
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Human immunodeficiency virus infection type 1 comparing Doravirine + lamivudine with Dolutegravir + lamivudine (2 arms). Primary endpoint: Virological failure at week 48. Planned start Jan 2025; status: authorised.
02
Drugs
doravirinedolutegravirlamivudine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2024-515793-27-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515793-27-01.